Literature DB >> 11111207

Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice.

M C Michel1, M Goepel.   

Abstract

Randomised controlled trials (RCTs) are an important scientific tool to determine the efficacy and tolerability of a given treatment relative to placebo or other treatment forms. However, due to strict inclusion and exclusion criteria the patient populations in RCTs may not be fully representative for those routinely consulting the physician. Moreover, participation in a formal study puts physician and patient in a situation where they may react different than in real life. In contrast real life practice (RLP) studies cannot determine treatment efficacy or tolerability in absolute terms since they typically do not include a control group and are purely observational. On the other hand, they tend to be more representative for real treatment outcomes. Thus, RCTs have high internal but less external validity whereas RLP studies have less internal and greater external validity. Hence, RCTs and RLP studies should not be considered as mutually exclusive but rather as complementing each other. Specific advantages and disadvantages of RCTs and RLP studies will be discussed using published evidence for the treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction with alpha1-adrenoceptor antagonists and other treatments.

Entities:  

Mesh:

Year:  2000        PMID: 11111207     DOI: 10.1159/000052400

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

Review 1.  Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage.

Authors:  Andrea Tubaro; Simon Carter; Alberto Trucchi; Giorgio Punzo; Stefano Petta; Lucio Miano
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

2.  Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease.

Authors:  Heike Rau-Berger; Harald Mitfessel; Thomas Glaab
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-10-10

3.  Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study.

Authors:  Martin C Michel; Ulrich Wetterauer; Monika Vogel; Jean J M C H de la Rosette
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Considering usual medical care in clinical trial design.

Authors:  Liza Dawson; Deborah A Zarin; Ezekiel J Emanuel; Lawrence M Friedman; Bimal Chaudhari; Steven N Goodman
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

5.  Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.

Authors:  Rüdiger Sauer; Michaela Hänsel; Roland Buhl; Roman A Rubin; Marcel Frey; Thomas Glaab
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-04-27

6.  What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine.

Authors:  A Elif Müderrisoglu; Matthias Oelke; Tim Schneider; Sandra Murgas; Jean J M C H de la Rosette; Martin C Michel
Journal:  Adv Ther       Date:  2022-03-24       Impact factor: 4.070

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.